A PYMNTS Company

GlaxoSmithKline to pay $2.6 million for inflating Idaho Medicaid drug prices

By  |  April 17, 2012

GlaxoSmithKline has agreed to pay the state of Idaho $2.6 million to settle claims that it overcharged Idaho Medicaid. Idaho Attorney General Lawrence Wasden believes that the manufacturer inflated the average wholesale price of its drugs; for example, the price of Wellbutrin was found to be inflated by as much as 27 percent. Of the $2.6 million settlement, $1.544 million will go into the Cooperative Welfare Fund to reimburse the federal government. The remainder will go to the state: more than $620,000 will be deposited into the state’s general fund, and $50,000 will go into the consumer protection account for the Attorney General’s investigative and legal costs.

Full content: Idaho Statesman

 

Related content: Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements (Anne Layne-Farrar, Compass Lexecon)

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.